THC Therapeutics (THC Therapeutics) Interest Expense : $-0.08 Mil (TTM As of Jul. 2023)

View and export this data going back to 2007. Start your Free Trial

What is THC Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. THC Therapeutics's interest expense for the three months ended in Jul. 2023 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jul. 2023 was $-0.08 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. THC Therapeutics's Operating Income for the three months ended in Jul. 2023 was $ -0.06 Mil. THC Therapeutics's Interest Expense for the three months ended in Jul. 2023 was $ -0.02 Mil. THC Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

THC Therapeutics Interest Expense Historical Data

The historical data trend for THC Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

THC Therapeutics Interest Expense Chart

THC Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Interest Expense

Get a 7-Day Free Trial

-0.30

-0.49

-0.55

-0.10

-0.08

THC Therapeutics Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Interest Expense	Get a 7-Day Free Trial															0.01	-0.02	-0.02	-0.02	-0.02

THC Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08 Mil.

THC Therapeutics (OTCPK:THCT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

THC Therapeutics's Interest Expense for the three months ended in Jul. 2023 was $-0.02 Mil. Its Operating Income for the three months ended in Jul. 2023 was $-0.06 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jul. 2023 was $0.00 Mil.

THC Therapeutics's Interest Coverage for the quarter that ended in Jul. 2023 is calculated as

THC Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

THC Therapeutics (THC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » THC Therapeutics Inc (OTCPK:THCT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

11700 W Charleston Boulevard, No. 73, Las Vegas, NV, USA, 89135

Website

https://thct.io

THC Therapeutics Inc is a United States-based company. It is focused on developing dHydronator, a sanitizing herb dryer. The main function of the dHydronator is to accelerate the drying time of an herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis. It will reduce the drying time for cannabis from 10-14 days down to less than 14 hours.

Executives

Hiro Tanaka	director, officer: Vice President	3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Smith Adrian J R	director, officer: Chair of the Board	119 SPRINGLINE DRIVE, VERO BEACH FL 32963
Jamie Mann	director, 10 percent owner, officer: CEO, CFO	3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Eden Ho	director, officer: CEO	701 XUANG MI HU ROAD, XI YUAN, FUTIAN, SHENZHEN F4 XXXXXX